JAK inhibitor Tofacitinib, Purity ≥98%

Synonym: Tofacitinib; 477600-75-2; Tasocitinib; 3-((3R,4R)-4-Methyl-3-(methyl(7S-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; JAK inhibitor

MDL: MFCD11035919
CAS Number: 477600-75-2
Compound CID: 9926791

Product Size

50 mg; 100 mg; 250 mg; 500 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

Tofacitinib, soluble in warmed DMSO and insoluble in water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, Lck, and Rock-II.

Molecular Weight

312.37

Molecular Formula

C₁₆H₂₀N₆O

Targets

JAK1: 112 nM; JAK2: 20 nM; JAK3: 1 nM; Lck: 3870 nM; Rock-II: 3400 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

Warmed DMSO: 56 mg/mL (179.27 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Stability

The product is stable for three years when stored at the recommended temperature in lyophilized powder.

Applications

Tofacitinib can be used to investigate its JAK1/3 inhibition for research in rheumatoid arthritis and other inflammatory diseases.

Storage

Store at -20ºC.